The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Hackensack University Medical Center; Regional Cancer Care Associates
Stock and Other Ownership Interests - COTA
Honoraria - Acerta Pharma; AstraZeneca; Celgene; Janssen; Kite/Gilead
Consulting or Advisory Role - Acerta Pharma; AstraZeneca; Celgene; COTA; Janssen; Kite/Gilead
Research Funding - Acerta Pharma; AstraZeneca; Genentech; Hackensack University Medical Center; Pharmacyclics; University of Nebraska Medical Center/ Research To Practice
Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).
 
Michael Wang
Honoraria - Acerta Pharma; AstraZeneca; BeiGene; Breast-Gynecological International Cancer Society; CAHON; Chinese Anti-Cancer Association; Chinese Medical Association; Clinical Care Options; Dava Oncology; Epizyme; Hebei Cancer Prevention Federation; Imedex; Janssen Research & Development; Kite, a Gilead company; Miltenyi Biomedicine; Moffit Cancer Center; Mumbai Hematology Group; Newbridge Pharmaceuticals; OM Pharmaceutical Industries; Pharmacyclics/Janssen; Physicans' Education Resource; Scripps Health; The First Affiliated Hospital of Zhejiang University
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; Bioinvent; CStone Pharmaceuticals; DTRM; Epizyme; Genentech; Guidepoint Global; Innocare; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Loxo; Miltenyi Biomedicine; Oncternal Therapeutics; Pharmacyclics/Janssen; Pulse Biosciences; VelosBio
Research Funding - Acerta Pharma; AstraZeneca; BeiGene; Bioinvent; Celgene; Innocare; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Lilly; Loxo; Molecular Templates; Oncternal Therapeutics; Pharmacyclics; VelosBio
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries
 
Wojciech Jurczak
Consulting or Advisory Role - AstraZeneca; Debiopharm Group; Epizyme; Janssen-Cilag; Roche
Research Funding - Acerta Pharma; Bayer; BeiGene; Debiopharm Group; Epizyme; Incyte; Janssen-Cilag; MEI Pharma; Morphosys; Roche; Sandoz-Novartis; Takeda; TG Therapeutics; TG Therapeutics
 
Mats Jerkeman
Honoraria - Abbvie; Celgene; Genmab; Gilead Sciences; Incyte; Janssen-Cilag; Novartis; Roche
Consulting or Advisory Role - Gilead Sciences
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Gilead Sciences (Inst); Janssen-Cilag (Inst); Roche (Inst)
 
Judith Trotman
Research Funding - Beigene (Inst); celgene (Inst); Janssen-Cilag (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Pier Luigi Zinzani
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb; Celltrion; EUSA Pharma; Gilead Sciences; Incyte; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Novartis; Roche; Sandoz; Secura BIO; SERVIER; Takeda; TG Therapeutics
Speakers' Bureau - EUSA Pharma; MSD; Novartis
 
Jan Andrzej Walewski
Honoraria - Abbvie; Gilead Sciences; Novartis; Roche
Consulting or Advisory Role - Abbvie; Gilead Sciences; Novartis; Roche; Takeda/Millennium
Research Funding - AstraZeneca/MedImmune; BMS; Epizyme; Incyte; Janssen-Cilag; Karyopharm Therapeutics; Loxo/Lilly; MorphoSys; MSD Oncology; NanoVector; Regeneron; Seagen; Takeda; TG Therapeutics; Vanda Pharmaceuticals
 
Jun Zhu
No Relationships to Disclose
 
Stephen Spurgeon
Consulting or Advisory Role - AstraZeneca
Research Funding - Acerta Pharma; BeiGene; Bristol-Myers Squibb/Celgene; Genentech; Gilead Sciences; Janssen; Merck; Schrodinger
 
Andre Goy
No Relationships to Disclose
 
Paul A. Hamlin
Employment - Agios (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Calithera Biosciences; Imbrium Therapeutics; watermark; Xcenda
Research Funding - GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); molecular templates (Inst); Portola Pharmaceuticals (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst)
 
David Belada
Consulting or Advisory Role - Debiopharm Group; Gilead Sciences; Janssen-Cilag; MorphoSys; Roche; Takeda
Research Funding - Dr. Reddy's (Inst); Genmab (Inst); Gilead Sciences (Inst); Janssen-Cilag (Inst); MorphoSys (Inst); Pharmacyclics (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Roche; Takeda
 
Muhit Ozcan
Research Funding - Abbvie; Acerta Pharma/AstraZeneca; Archigen Biotech; Bayer; Celgene; Janssen; MSD; Roche/Genentech; Takeda
 
John Storring
Honoraria - Abbvie; Astellas Pharma; Bristol-Myers Squibb/Celgene; Novartis; Pfizer; Taiho Oncology
Consulting or Advisory Role - Abbvie; Amgen; Astellas Oncology; Bristol-Myers Squibb/Celgene; Jazz Pharmaceuticals; Novartis; Paladin; Pfizer; Taiho Oncology; Teva
Research Funding - Abbvie; Astellas Oncology; Bristol-Myers Squibb/Celgene; Janssen; Novartis
 
David John Lewis
Consulting or Advisory Role - BeiGene; Lilly; Roche
 
Jose Angel Hernandez Rivas
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb/Celgene; Gilead Sciences; Janssen; Jazz Pharmaceuticals; Roche; ROVI; Takeda
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Gilead Sciences; Janssen; Jazz Pharmaceuticals; Lilly; Roche; ROVI; Takeda
Research Funding - Bristol-Myers Squibb/Celgene/Juno
 
Todd Henninger
Employment - Janssen
 
Sanjay Deshpande
Employment - Janssen
 
Rui Qin
Employment - Janssen
 
Steven Le Gouill
No Relationships to Disclose
 
Martin H. Dreyling
Consulting or Advisory Role - Abbvie/Genentech (Inst); Acerta Pharma/AstraZeneca; Amgen; Bayer/Vital; Beigene; Celgene/Jazz; Genmab; Gilead Sciences; Incyte; Janssen-Cilag; Lilly Medical; morphosys; Novartis; Roche
Speakers' Bureau - Amgen; Bayer Health; Beigene; Celgene; Gilead Sciences; Janssen-Cilag; Roche Pharma AG
Research Funding - Abbvie (Inst); Bayer (Inst); Celgene (Inst); Janssen-Cilag (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Celgene; Janssen-Cilag; Roche Pharma AG